SCHEMBL29914568

SCHEMBL29914568

FCCN1C[C@H]2C[C@@]2(c2ccc(Br)cc2)C1

nearest known ligand 0.48

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 4/20 0.46
DRD3 P35462 3/20 0.46
DRD2 P14416 2/20 0.46
BMPR1B O00238 4/20 0.43
BMPR1A P36894 4/20 0.43
TGFBR1 P36897 4/20 0.43
ACVRL1 P37023 4/20 0.43
ACVR1 Q04771 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13201887 0.92 KCNH2 (0.49) KCNH2DRD3DRD2
SCHEMBL8247741 0.92 KCNH2 (0.49) KCNH2DRD3DRD2
SCHEMBL4629032 0.92 KCNH2 (0.49) KCNH2DRD3DRD2
SCHEMBL3769912 0.83 KCNH2 (0.52) KCNH2DRD3DRD2
SCHEMBL11915231 0.83 KCNH2 (0.52) KCNH2DRD3DRD2
SCHEMBL3397256 0.83 KCNH2 (0.52) KCNH2DRD3DRD2
SCHEMBL13823162 0.83 KCNH2 (0.49) KCNH2DRD3DRD2
SCHEMBL11911756 0.83 KCNH2 (0.52) KCNH2DRD3DRD2
SCHEMBL12313185 0.83 KCNH2 (0.52) KCNH2DRD3DRD2
SCHEMBL3769913 0.83 KCNH2 (0.52) KCNH2DRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117597340-A Substituted amino-aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) 安大略省癌症研究所(OICR) 2024-02-23 CN disclosed
WO-2022226667-A1 SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed
WO-2022226666-A1 SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-11-03 WO disclosed